Clinical Trial Search

Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants

Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…

Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00

Primary: Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N) — 58.8; 78.4; 77.0 Percentage of…

Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale

Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05

Primary: Number of Participants Who Responded — 7; 4 participants

Primary: Number of Participants With Treatment Failure at 5 Years — 33; 19 participants

Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…

Primary: Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles…

Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants

Primary: Complete Response — 81 Participants

Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…

Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)

Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters

Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 75; 80; 20.3; 14.9 Percentage…

Primary: Change in Inflammation Biomarker Tissue PGE2 Level — 1.35; -0.02; 1.19; -0.06 nanograms/gram of tissue — p=0.30

Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74

Primary: The Rates of Complete Symptom Relief — 152; 157 participants — p=<0.05

Primary: Number of Dilation Procedures — 5.4; 2.4 Dilation procedures — p=0.159

Primary: Number of Patients With Esophageal Mucosa Healing — 28; 28; 32; 18 Participants

Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale

Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes

Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 78.4; 77.5; 16.6; 18.4…

Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale

Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms

Primary: Gastroesophageal Reflux Disease Health Related Quality of Life Outcome (GERD-HRQL) — 4.2; 4.9 score on a scale

Primary: Rate of Non-recurrence at Week 52 — 44.8; 73.9; 55.2; 26.1 Percentage of participants — p=<0.001

Primary: Number of Gastroesophageal Refluxes — 42.4 refluxes — p=0.000002

Primary: Eradication of Barrett's Esophagus — 2 Participants